← Back to Clinical Trials
Recruiting NCT06650813

NCT06650813 Adapting the FACETS Program to Sickle Cell Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06650813
Status Recruiting
Phase
Sponsor Versailles Hospital
Condition Fatigue Symptom
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2025-01-10
Primary Completion 2026-05-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Drépa-FACETS Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2025-01-10 with a primary completion date of 2026-05-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Adaptation of a fatigue management program combining the principles of cognitive-behavioral therapy and energy conservation strategies (FACETS program) for a population of adult patients with sickle cell disease (Drépa-FACETS program).

Eligibility Criteria

Inclusion Criteria: * Participant having freely given his oral agreement. * Participant with a major sickle cell syndrome, regardless of genotype (e.g. SS, SC, Sbeta). * Participant with a sufficient command of spoken and written French to take the assessments, complete the questionnaires, follow the program sessions and carry out the home exercises. Exclusion Criteria: * Participant with one or more severe psychiatric pathologies (e.g. severe depression, psychosis) that could interfere with the conduct of the study, in particular the primary and secondary endpoints. * Participants with another chronic pathology causing fatigue. * Participants in vaso-occlusive crisis (VOC) or hospitalization. * Participant under legal protection (guardianship, curatorship, safeguard of justice, deprived of liberty).

Contact & Investigator

Central Contact

Michalina DANNOUNE

✉ mdannoune@ght78sud.fr

📞 0139638856

Principal Investigator

Marie-Claire GAY, Pr

STUDY DIRECTOR

Paris Nanterre University

Frequently Asked Questions

Who can join the NCT06650813 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Fatigue Symptom. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06650813 currently recruiting?

Yes, NCT06650813 is actively recruiting participants. Contact the research team at mdannoune@ght78sud.fr for enrollment information.

Where is the NCT06650813 trial being conducted?

This trial is being conducted at Grenoble, France, Le Chesnay, France.

Who is sponsoring the NCT06650813 clinical trial?

NCT06650813 is sponsored by Versailles Hospital. The principal investigator is Marie-Claire GAY, Pr at Paris Nanterre University. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology